Relmada's Stock Moves Higher As Its Major Depressive Disorder Candidate Shows Lack Of Abuse Potential

Relmada Therapeutics Inc RLMD has announced positive top-line results from the human abuse potential (HAP) study with REL-1017 for major depressive disorder (MDD).
Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in recreational opioid users demonstrated a highly statistically significant difference vs. the active control drug, oxycodone 40 mg.
The study's primary endpoint was a measure of "likability" with the subjects rating the maximum effect (or Emax) for Drug Liking "at the moment," with 100 as the highest likability, 50 as neutral (placebo-like), and 0 the highest dislike.
Mean Emax for Drug Liking for REL-1017 at 25, 75, and 150 mg doses were 53.0, 58.2, 64.9, respectively, compared to 51.7 for placebo and 85.0 for Oxycodone 40 mg.
Prior preclinical and clinical findings have indicated that the dextro-isomer REL-1017 lacks its parent molecule's addiction liability and respiratory depressant effects.
Price Action: RLMD shares are up 27.1% at $31.93 during the premarket session on the last check Tuesday.